Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

Overview of attention for article published in Lancet Neurology, January 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 4 public wall posts from 4 users.

Autologous Mesenchymal Stem Cell for Treatment of MS Shows Evidence of Structural, Functional, and Physiological Improvement…

درمان ام اس ثانویه با سلول بنیادی مزانشیمال - مطالعه دانشگاه کمبریج Lancet Neurol. 2012 February; 11(2): 150–156. doi: …

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of…

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.